QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 d-boral-capital-maintains-buy-on-compass-therapeutics-maintains-32-price-target

D. Boral Capital analyst Jason Kolbert maintains Compass Therapeutics (NASDAQ:CMPX) with a Buy and maintains $32 price target.

 guggenheim-maintains-buy-on-compass-therapeutics-raises-price-target-to-12

Guggenheim analyst Michael Schmidt maintains Compass Therapeutics (NASDAQ:CMPX) with a Buy and raises the price target from ...

 compass-therapeutics-q2-eps-014-misses-012-estimate

Compass Therapeutics (NASDAQ:CMPX) reported quarterly losses of $(0.14) per share which missed the analyst consensus estimate o...

 raymond-james-reinstates-outperform-on-compass-therapeutics-announces-9-price-target

Raymond James analyst Sean McCutcheon reinstates Compass Therapeutics (NASDAQ:CMPX) with a Outperform and announces $9 price...

 compass-therapeutics-q1-eps-012-misses-011-estimate

Compass Therapeutics (NASDAQ:CMPX) reported quarterly losses of $(0.12) per share which missed the analyst consensus estimate o...

 d-boral-capital-maintains-buy-on-compass-therapeutics-maintains-32-price-target

D. Boral Capital analyst Jason Kolbert maintains Compass Therapeutics (NASDAQ:CMPX) with a Buy and maintains $32 price target.

 compass-therapeutics-announces-its-poster-presentation-entitled-enhanced-efficacy-of-ctx-471-a-cd137-agonist-antibody-in-models-of-immune-checkpoint-failure-via-simultaneous-blockade-of-neo-angiogenesis-american-association-for-cancer-research-annual-meeting-april-2530-2025-in-chicago-illinois

CTX-471 monotherapy demonstrated efficacy in multiple murine models, including models highly resistant to immune checkpoint inh...

 guggenheim-reiterates-buy-on-compass-therapeuticsto-buy

Guggenheim analyst Michael Schmidt reiterates Compass Therapeutics (NASDAQ:CMPX) from Buy to Buy.

 hc-wainwright--co-reiterates-buy-on-compass-therapeutics-maintains-24-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Compass Therapeutics (NASDAQ:CMPX) with a Buy and maintains $24 ...

 d-boral-capital-maintains-buy-on-compass-therapeutics-maintains-32-price-target

D. Boral Capital analyst Jason Kolbert maintains Compass Therapeutics (NASDAQ:CMPX) with a Buy and maintains $32 price target.

 hc-wainwright--co-maintains-buy-on-compass-therapeutics-raises-price-target-to-24

HC Wainwright & Co. analyst Joseph Pantginis maintains Compass Therapeutics (NASDAQ:CMPX) with a Buy and raises the pric...

 guggenheim-reiterates-buy-on-compass-therapeutics-maintains-12-price-target

Guggenheim analyst Michael Schmidt reiterates Compass Therapeutics (NASDAQ:CMPX) with a Buy and maintains $12 price target.

 leerink-partners-upgrades-compass-therapeutics-to-outperform-raises-price-target-to-6

Leerink Partners analyst Andrew Berens upgrades Compass Therapeutics (NASDAQ:CMPX) from Market Perform to Outperform and rai...

 small-cap-compass-therapeutics-shares-positive-primary-goal-data-from-pivotal-cancer-drug-study-for-biliary-tract-cancer

Compass Therapeutics' Phase 2/3 trial shows tovecimig plus paclitaxel significantly improves response rates in advanced bil...

 d-boral-capital-maintains-buy-on-compass-therapeutics-maintains-32-price-target

D. Boral Capital analyst Jason Kolbert maintains Compass Therapeutics (NASDAQ:CMPX) with a Buy and maintains $32 price target.

 compass-therapeutics-announced-statistically-significant-top-line-data-on-the-primary-efficacy-endpoint-for-companion-002-the-companys-ongoing-phase-23-trial-of-tovecimig-formerly-ctx-009-in-combination-with-paclitaxel-in-patients-with-advanced-biliary-tract-cancer

Tovecimig (a DLL4 x VEGF-A bispecific antibody) in combination with paclitaxel achieved a 17.1% overall response rate (ORR), in...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION